Please refer letter in relation to reappointment of Managing Director-Dr Ashish Rawandale.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tejnaksh Healthcare Ltd has informed BSE about the reappointment of Dr. Ashish Rawandale as Chairman & Managing Director for a further period of 5 years, effective 27th March 2025. The reappointment is subject to shareholder approval at the company's next general meeting. Dr. Rawandale is the promoter of the company and a renowned urologist holding multiple records in Guinness, Limca and Asia Book of Records, along with 150+ academic publications. His spouse, Dr. Preeti Rawandale, serves as a Non-Executive Director from the promoter group. The intimation was filed on 19 May 2025 under SEBI LODR Regulation 30.
This is a routine reappointment of the existing promoter-MD, ensuring leadership continuity for the next five years. No material change in strategy or governance is expected, though shareholder approval at the next general meeting is still required to formalize it.